CCL2 and CCR4 or CCR2 have been proposed as a potential target for decreasing myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) recruitment in prostate cancer, breast cancer, malignant glioma, colorectal cancer, and lung carcinoma. Here, CCR4 is linked to breast carcinoma.